Cargando…

QSAR modelling and molecular docking studies for anti-cancer compounds against melanoma cell line SK-MEL-2

A dataset of seventy-two (72) cytotoxic compounds of the National Cancer Institute (NCI) was studied by QSAR and docking approaches to gain deeper insights into ligands selectivity on SK-MEL-2 cell line. The QSAR model was built using fifty (50) molecules and the best-generated model based on multip...

Descripción completa

Detalles Bibliográficos
Autores principales: Umar, Abdullahi Bello, Uzairu, Adamu, Shallangwa, Gideon Adamu, Uba, Sani
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7110328/
https://www.ncbi.nlm.nih.gov/pubmed/32258485
http://dx.doi.org/10.1016/j.heliyon.2020.e03640
Descripción
Sumario:A dataset of seventy-two (72) cytotoxic compounds of the National Cancer Institute (NCI) was studied by QSAR and docking approaches to gain deeper insights into ligands selectivity on SK-MEL-2 cell line. The QSAR model was built using fifty (50) molecules and the best-generated model based on multiple linear regression showed, respectively good quality of fits ([Formula: see text] (0.864), [Formula: see text] (0.845), Q(2)(cv) (0.799) and [Formula: see text] (0.706)). The model's predictive ability was determined by a test set of twenty-two (22) compounds. Compounds 30 and 41 were selected as templates for in silico design because they had high pGI(50) activity and are in the model's applicability domain. The obtained information from the model was explored to design novel molecules by introducing various modifications. Moreover, the designed compounds with better-predicted activity (pGI(50)) values were selected and docked on the active site of the protein (PDB-CODE: 3OG7) which is responsible for melanoma cancer to elucidate their binding mode. AN2 (−12.1kcalmol(-1)) and AC4 (−12.4kcalmol(-1)) showed a better binding score for the target when compared with (vemurafenib, −11.3kcalmol(-1)) the known inhibitor of the target (V600E-BRAF). These findings may be very helpful in early anti-cancer drug development.